Atherogenic properties of human monocytes induced by the carboxyl terminal proteolytic fragment of alpha-1-antitrypsin

Atherosclerosis

Volumn 147, Issue 2, 1999, Pages 263-275

  Janciauskiene, S ^a   Wright, H T ^b   Lindgren, S ^a  

^a Dept of Medicine   (Sweden)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Alpha 1 antitrypsin; Atherogenesis; Cytokines; Human monocytes; Lipid oxidation

Indexed keywords

ALPHA 1 ANTITRYPSIN; GLUTATHIONE REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CYTOKINE PRODUCTION; FOAM CELL; HUMAN; HUMAN CELL; INFLAMMATION; LIPID OXIDATION; MONOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALPHA 1-ANTITRYPSIN; ANALYSIS OF VARIANCE; ANTIGENS, CD36; APOPTOSIS; ARTERIOSCLEROSIS; CELLS, CULTURED; CYTOKINES; GLUTATHIONE REDUCTASE; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MACROPHAGE ACTIVATION; MONOCYTES; PEPTIDE FRAGMENTS; RECEPTORS, LDL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0032713568     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00194-X     Document Type: Article

References (60)

1. Schmitz G., Herr A.S., Rothe G. T-lymphocytes and monocytes in atherogenesis. Herz. 23:1998;168-177.
2. McEvoy L.M., Jutila M.A., Tsao P.S., Cooke J.P., Butcher E.C. Anti-CD43 inhibits monocyte-endothelial adhesion in inflammation and atherogenesis. Blood. 90:1997;3587-3594.
3. Murakami T., Yamada N. Modification of macrophage function and effects on atherosclerosis. Curr. Opin. Lipidol. 7:1996;320-323.
4. Smith E.B. Molecular interactions in human atherosclerotic plaques. Am. J. Pathol. 86:1977;665-674.
5. Hollander W., Colombo M.A., Kirkpatrick B., Paddock J. Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, α1-antitrypsin and α2-macroglobulin. Atherosclerosis. 34:1979;391-405.
6. Travis J., Salvesen G.S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52:1983;655-709.
7. Perlmutter D.H., Cole F.S., Kilbridge T.H., Rossing T.H., Colten H.R. Expression of α-1-proteinase inhibitor gene in human monocytes and macrophages. Proc. Natl. Acad. Sci. 82:1985;795-799.
8. Issacson P.D., Jones D.B., Milward-Sadler G.H., Judd M.A., Payne S. Alpha-1-antitrypsin in human macrophages. J. Clin. Pathol. 34:1981;982-990.
9. Knoell D.L., Ralston D.R., Coulter K.R., Wewers M.D. Alpha1-antitrypsin and protease complexation is induced by lipopolysacchride, interleukin-1β in monocytes. Am. J. Respir. Crit. Care Med. 157:1998;246-255.
10. Perlmuter D.H., Punsal P.I. Distinct and additive of elastase and endotoxin on expression of α1 proteinase inhibitor in mononuclear phagocytes. J. Biol. Chem. 263:1988;16499-16503.
11. Perlmutter D.H., May L.T., Sehgal P.B. Interferon β2/interleukin 6 modulates synthesis of α1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J. Clin. Invest. 84:1989;138-144.
12. Carrell R.W., Stein P.E. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol. Chem. Hoppe-Seyler. 377:1996;1-17.
13. Carrell R.W., Lomas D.A. Conformational disease. Lancet. 350:1997;134-138.
14. Bruch M., Weiss V., Engel J. Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and large increase in conformational stability upon cleavage at their reactive sites. J. Biol. Chem. 263:1988;166626-166630.
15. Engh R.A., Schulze A.J., Huber R., Bode W. Serpin structures. Behring Inst. Mit. 93:1993;41-62.
16. Joslin G., Fallon R.J., Bullock J., Adams S.P., Perlmutter D.H. The SEC receptor recognizes a pentapeptide neodomain of α1-antitrypsin-protease complexes. J. Biol. Chem. 266:1991;11281-11288.
17. Paakko P., Kirby M., du Bois R.M., Gillisen A., Ferrans J., Crystal R.G. Activated neutrophils secrete stored α1-antitrypsin. Am. J. Respir. Crit. Med. 154:1996;1829-1833.
18. Michaelis J., Vissers M.C., Winterbourn C.C. Human neutrophil collagenase cleaves α-1-antitrypsin. Biochem. J. 270:1990;809-814.
19. Winyard P.G., Zhang Z., Chidwick K., Blake D.R., Carrell R.W., Murphy G. Proteolytic inactivation of human α-1-antitrypsin by human stromelysin. FEBS Lett. 279:1991;91-94.
20. Potempa J., Watorek W., Travis J. The inactivation of human plasma α-1-proteinase inhibitor by proteinases from Staphylococcus aureus. J. Biol. Chem. 254:1979;5317-5320.
21. Virca G.D., Lyerly D., Kreger A., Travis J. Inactivation of human plasma α-1-proteinase inhibitor by a metalloproteinase from Serratia marcescens. Biochim. Biophys. Acta. 704:1982;267-271.
22. Morihara K., Tsuzuki H., Harada M., Iwata T. Purification of human plasma α-1-proteinase inhibitor and its inactivation by Pseudomonas aeruginosa elastase. J. Biochem. Tokyo. 95:1984;795-804.
23. Johansson J., Gröndal S., Sjövall J., Jörnvall H., Curstedt T. Identification of hydrophobic fragments of α-antitrypsin and C1 protease inhibitor in human bile, plasma and spleen. FEBS Lett. 299:1992;146-148.
24. Niemann M.A., Narkates A.J., Miller A.J. Isolation and serine proteinase activity of the 44-residue C-terminal fragment of α-1-antitrypsin from human placenta. Matrix. 12:1992;233-241.
25. Ray M.B., Geboes K., Callea F., Desmer V.J. Alpha-1-antitrypsin immunoreactivity in islet cells of adult human pancreas. Cell Tissue Res. 185:1977;63-68.
26. Geboes K., Ray M.B., Rutgeerts P., Callea F., Desmet V.J., Vantrappen G. Morphological identification of α-1-antitrypsin in the human small intestine. Histopathology. 6:1982;55-60.
27. Niemann M.A., Baggott J.E., Miller E.J. Binding of SPAAT, the 44-residue C-terminal peptide of α-1-antitrypsin, to proteins of the extracellular matrix. J. Cell. Biochem. 66:1997;346-357.
28. Barbey-Morel C., Perlmutter D.H. Effect of pseudomonas elastase on human mononuclear phagocyte α-1-antitrypsin expression. Pediatr. Res. 29:1991;133-140.
29. Janciauskiene S., Al Rayyes O., Floren C.-H., Eriksson S. Low density lipoprotein catabolism is enhanced by the cleaved form of α-1-antitrypsin. Scand. J. Clin. Lab. Invest. 57:1997;325-336.
30. Mirzabekov T.A., Lin M., Kagan B.L. Pore formation by the cytotoxic istel amyloid peptide amylin. J. Biol. Chem. 271:1996;1988-1992.
31. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-827.
32. Lorenzo A., Yankner B.A. Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann. New York Acad. Sci. 777:1996;89-95.
33. Janciauskiene S., Carlemalm E., Eriksson S. In vitro fibril formation from α-1-antitrypsin-derived C-terminal peptides. Biol. Chem. Hoppe-Seyler. 376:1995;415-423.
34. Janciauskiene S., Lindgren S., Wright T.H. The C-terminal peptide of α-1-antitrypsin increases low density lipoprotein binding in HepG2 cells. Eur. J. Biochem. 254:1998;460-467.
35. Janciauskiene S., Lindgren S. Effects of fibrillar C-terminal fragment of cleaved α-1-antitrypsin on cholesterol homeostasis in HepG2 cells. Hepatology. 29:1999;434-442.
36. Mc Farlane A.S. Efficient trace-labelling of proteins with iodine [Abstract]. Nature. 182:1958;53.
37. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurements with folin phenol reagents. J. Biol. Chem. 193:1951;265-275.
38. Böyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand. J. Immunol. Suppl. 5:1976;9-15.
39. Davis L.G., Dibner M.D., Battey J.F. Preparation and analysis of RNA from eukaryotic cells. Davis L.G. Basic Methods in Molecular Biology. 1986;129-156 Elsevier, New York.
40. Choczynski P., Nicoletta S. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
41. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K. Short Protocols in Molecular Biology. 1995;10:80 Wiley, New York.
42. Lin P.H., Selinfreund R., Wharton W. Isolation of cell membranes for epidermal growth factor receptor studies. Methods Enzymol. 198:1991;251-259.
43. Gavey K.L., Noland B.J., Scallen T.J. The participation of sterol carrier protein2 in the conversion of cholesterol to cholesterol ester by rat liver microsomes. J. Biol. Chem. 256:1981;2993-2999.
44. Norusis M.J. SPSS for Windows, rel. 6.0. 1993;SPSS Inc, Chicago, IL.
45. Ikeda U., Takahashi M., Shimada K. Monocyte-endothelial cell interaction in atherogenesis and thrombosis. Clin. Cardiol. 21:1998;11-14.
46. Libby P., Geng Y.J., Aikawa M., Schoenbeck U., Mach F., Clinton S.K., Sukhova G.K., Lee R.T. Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 7:1996;330-335.
47. Hiltunen T.P., Luoma J.S., Nikkari T., Yla-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation. 97:1998;1079-1089.
48. Weiss S.J., King G.W., LoBuglio A.F. Evidence for hydroxyl radical generation by human monocytes. J. Clin. Invest. 60:1977;370-373.
49. Watanabe T., Haraoka S., Shimokama T. Inflammatory and immunological nature of atherosclerosis. Int. J. Cardiol. 54(Suppl.):1996;S51-S60.
50. Abbink J.J., Kamp A.M., Swaak A.J., Hack C.E. Production of monoclonal antibodies against inactivated α-1-antitrypsin. Cross-reactivity with complexed α-1-antitrypsin and application in an assay to determine inactivated and complexed α-1-antitrypsin in biological fluids. J. Immunol. Methods. 143:1991;197-208.
51. Desrochers P.E., Mookhtiar K., Van Wart H.E., Hasty K.A., Weiss S.J. Proteolytic inactivation of α1-proteinase inhibitor and α1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J. Biol. Chem. 267:1992;5005-5012.
52. Mast A.E., Enghild J.J., Nagase H., Suzuki K., Pizzo S.V., Salvesen G. Kinetics and physiologic relevance of the inactivation of α1-proteinase inhibitor, α1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). J. Biol. Chem. 266:1991;15810-15816.
53. Stockley R.A., Shaw J., Afford S.C., Morrison H.M., Burnett D. Effect of α-1-proteinase inhibitor on neutrophil chemotaxis. Am. J. Respir. Cell. Mol. Biol. 2:1990;163-170.
54. Matsuure F., Yamashita S., Hirano K., Ishigami M., Hiraoka H., Tamura R., Nakagawa T., Nishida M., Sakai N., Nakamura T., Nozaki S., Funahashi T., Matsumoto C., Higashiyama M., Yoshikawa K., Matsuwa Y. Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia - a possible pathogenesis of necrobiotic xanthogranuloma. Atherosclerosis. 142:1999;355-365.
55. Badman M.K., Pryce R.A., Charge S.B.P., Morris J.F., Clark A. Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. Cell Tissue Res. 291:1998;285-294.
56. Richter J., Gullberg U., Lantz M. TNF-induced superoxide anion production in adherent human neutrophils involves both the p55 and p75 TNF receptors. J. Immunol. 154:1995;4142-4149.
57. Steinberg D. Modified forms of low-density lipoprotein and atherosclerosis. J. Int. Med. 233:1993;227-232.
58. Calvo D., Gomez-Coronado D., Suarez Y., Lasuncion M.A., Vega M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid Res. 39:1998;777-788.
59. Nakagawa T., Nozaki S., Nishida M., Yakub J.M., Tomiyama Y., Nakata A., Matsumoto K., Funahashi T., Kameda-Takemura K., Kurata Y., Yamashita S., Matsuzawa Y. Oxidized LDL increases and interferon-γ decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 18:1998;1350-1357.
60. Xing X., Baffic J., Sparrow C.P. LDL oxidation by activated monocytes: characterization of the oxidized LDL and requirement for transition metal ions. J. Lipid Res. 39:1998;2201-2208.